Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 223

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 10
Chunk 223
---
164 
  
    Borrowings under related
    party line of credit 
     -  
     1,452,414 
  
    Proceeds from warrant exercises 
     37,300  
     - 
  
    Proceeds
    from sale of common stock 
     6,832,973  
     1,000,000 
  
    Net cash provided
    by financing activities 
     6,335,328  
     3,859,608 

    Net increase (decrease) in cash 
     1,264,900  
     (188)
  
    Cash,
    beginning of year 
     1,231  
     1,419 
  
    Cash,
    end of year 
    $1,266,131  
    $1,231 

    Supplemental disclosure
    of Cash Flow Information 

    Cash paid for interest 
     $-  
     $- 
  
    Cash paid for income taxes 
     $-  
     $- 
  
    Supplemental schedule of
    non-cash financing activities: 

    Issuance of warrants on related party line
    of credit 
     $-  
    $5,950,000 
  
    Accrued offering expense 
     $-  
     $90,000 
  
    Debt conversion to common stock 
     $-  
     $3,100,579 
  
    Advances to affiliates 
     $-  
     $130,000 
  
    Deferred offering costs charged to additional paid-in capital 
    $303,281  
    $- 

The
accompanying notes to the financial statements are an integral part of these statements.

F-6

Telomir
Pharmaceuticals, Inc.

SUPPLEMENTAL
CASH FLOW INFORMATION

Non-cash
Operating, Financing and Investing Activities:

The
Company recorded the fair value of a total of 2,439,025 warrants issued to Bay Shore Trust during the year ended December 31, 2023 totaling
approximately $5.95 million to deferred finance costs.

The
Company accrued a $0.09
million placement fee related to a $1.0
million private placement offering during the
year ended December 31, 2023, whereby 268,025
shares of common stock (after giving effect to
our